APS — Aptose Biosciences Share News
0.000.00%
Last trade - 00:00- CA$6.12m
- CA$51.28m
Brief: Aptose Biosciences Inc Says Initiates Dosing Of Cg-806 In Patients With Acute Myeloid Leukemia
Canada Research Roundup: Aptose Biosciences, Canadian National Railway, TFI International
Brief: Aptose Reports Results For The Second Quarter 2020
Aptose Biosciences drops on stock deal
Brief: Aptose Announces Pricing Of Public Offering Of 10.5 Mln Common Shares
Brief: Aptose Announces Proposed Public Offering Of Common Shares
Brief: Aptose Announces FDA Allowance Of IND For Phase 1A/B Study Of Cg-806 In Acute Myeloid Leukemia
Brief: Aptose Presents Early Phase 1A/B CG-806 Clinical Findings
Brief: Aptose Biosciences Establishes New At-The-Market Facility
Brief: Aptose Reports Results For The First Quarter 2020
Brief: Aptose Presents Preliminary Clinical Data On CG-806
Nasdaq Trade Halt Market Wide Circuit Breaker Halt: LEVEL 1 AT 08:38 AM
Brief: Aptose Biosciences Files For Offering Of Common Shares, Warrants & Units Of Up To $200 Mln
Brief: Aptose Announces Pricing Of Public Offering Of Common Shares
Aptose Biosciences dips after pricing upsized stock deal
Brief: Aptose Announces Proposed Public Offering Of Common Shares
Aptose Biosciences slumps on stock offering
Positive data at ASH meet fires up cancer drugmakers
Brief: Aptose Presents New Preclinical Cg-806 Data At The 2019 Ash Annual Meeting